# Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

> **NCT03340129** · PHASE2 · RECRUITING · sponsor: **Melanoma Institute Australia** · enrollment: 218 (estimated)

## Conditions studied

- Melanoma Stage Iv

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **RADIATION:** Stereotactic Radiotherapy
- **OTHER:** Salvage therapy

## Key facts

- **NCT ID:** NCT03340129
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-14
- **Primary completion:** 2026-08
- **Final completion:** 2029-08
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03340129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03340129, "Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03340129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*